(0.16%) 5 139.50 points
(0.12%) 38 486 points
(0.23%) 17 887 points
(-0.04%) $83.82
(0.73%) $1.937
(0.23%) $2 352.70
(0.60%) $27.70
(2.04%) $940.95
(-0.23%) $0.933
(-0.41%) $10.98
(-0.35%) $0.798
(1.25%) $93.02
@ $49.81
发出时间: 15 Feb 2024 @ 04:43
回报率: -23.15%
上一信号: Feb 13 - 23:40
上一信号:
回报率: 1.67 %
Live Chart Being Loaded With Signals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity...
Stats | |
---|---|
今日成交量 | 305 047 |
平均成交量 | 570 825 |
市值 | 2.30B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $-2.12 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.96 |
ATR14 | $0.0460 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-14 | Mazabraud Yann | Sell | 10 375 | Common Stock |
2024-04-14 | Mazabraud Yann | Sell | 10 375 | Restricted Stock Units |
2024-04-15 | Mazabraud Yann | Buy | 10 000 | Restricted Stock Units |
2024-04-15 | Mazabraud Yann | Buy | 8 905 | Restricted Stock Units |
2024-04-15 | Mazabraud Yann | Sell | 6 874 | Restricted Stock Units |
INSIDER POWER |
---|
38.89 |
Last 100 transactions |
Buy: 1 143 191 | Sell: 502 628 |
音量 相关性
Rhythm Pharmaceuticals 相关性 - 货币/商品
Rhythm Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $77.43M |
毛利润: | $68.13M (87.99 %) |
EPS: | $-3.20 |
FY | 2023 |
营收: | $77.43M |
毛利润: | $68.13M (87.99 %) |
EPS: | $-3.20 |
FY | 2022 |
营收: | $23.64M |
毛利润: | $21.51M (90.98 %) |
EPS: | $-3.51 |
FY | 2021 |
营收: | $3.15M |
毛利润: | $2.56M (81.01 %) |
EPS: | $-1.400 |
Financial Reports:
No articles found.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。